CABG Medical Announces Initiation of CE Mark Clinical Trial
May 03 2005 - 11:52AM
PR Newswire (US)
CABG Medical Announces Initiation of CE Mark Clinical Trial
MINNEAPOLIS, May 3 /PRNewswire-FirstCall/ -- CABG Medical, Inc.
(NASDAQ:CABG) today announced the initiation of enrollment in its
clinical trial for CE Mark approval of the Holly Graft(TM) System,
a drug eluting graft (DEG) for facilitating a coronary artery
bypass procedure. (Logo:
http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO ) "The CE
Mark is the designation for approval in major markets outside the
United States and Japan," said Manny Villafana, Chairman and CEO.
"We are excited to begin this important work with some of the most
prominent cardiac surgery centers in the world." The first patient
enrolled in the Holly Graft System clinical trial (second patient
treated) was completed by Peter Tesar, M.D., and Trevor Fayers,
M.D., Cardiac Surgeons at the Prince Charles Hospital in Brisbane,
Australia. The surgeons in Australia also completed the first
implant of the Holly Graft System in November 2004. Mr. Villafana
continued, "We have worked closely with our scientific advisory
board and our physician collaborators over the past four years in
developing a technology that had a safety profile that was adequate
to move into human evaluation. The incorporation of the Paclitaxel
drug eluting technology into the Holly Graft System has made a
profound difference that could positively impact the effectiveness
of the device." CABG Medical management will be discussing the
clinical status of the Holly Graft(TM) System as well as other
topics at the Company's annual meeting, which will be held at the
Minneapolis Club, 729 Second Avenue South, Minneapolis, Minnesota
beginning at 3:30 p.m. (central daylight time) on Tuesday, May 3.
All interested parties are encouraged to attend the meeting or to
participate in a webcast through a link on the Company's website:
http://www.cabgmedical.com/ or
http://www.shareholder.com/cabg/MediaRegister.cfm?MediaID=15664
About CABG Medical CABG Medical, Inc. is a medical technology
company developing technologies and therapies to improve the
treatment of coronary heart disease by advancing conventional
bypass surgery. We have designed our first product, the Holly
Graft(TM) System, by leveraging our understanding of flow dynamics,
material sciences and drug combinations to create a drug-eluting
graft (DEG) system. Safe Harbor This Press Release contains
forward-looking statements that may include statements regarding
intent, belief or current expectations of the Company and its
management. Actual results could differ materially from those
projected in the forward looking statements as a result of a number
of important factors, including regulatory actions, competition,
and management of growth. For a discussion of these and other risks
and uncertainties that could affect the Company's activities and
results, please refer to the Company's filings with the Securities
and Exchange Commission.
http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO
http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT:
Manny Villafana, Chairman & CEO, or John L. Babitt, President
& COO, both of CABG Medical, Inc., +1-763-258-8005, FAX
+1-763-258-8008 Web site: http://www.cabgmedical.com/
Copyright
Cabg Medical (NASDAQ:CABG)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cabg Medical (NASDAQ:CABG)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Cabg Medical (MM) (NASDAQ): 0 recent articles
More Cabg Medical (MM) News Articles